MDGL stock information

Sector:

Healthcare

Description:

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc. website

Current Price

$259.94

RSI

18.68

Market Capitalization:

1.1B

Beta:

0.907

Volume:

477,572

Analyst Target Price:

$ 152.58

Economiic Fair Price:

Earnings DateNovember 02, 2022

Report DateNovember 03, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash

Debt

EPS-14.65

Profit MarginN/A

Revenue Per Share TTM0

Return On Equity TTM-2.232

2021 Free Cash Flow

$ -184.1M

-16.61 %

2020 Free Cash Flow

$ -157.9M

-277.78 %

2019 Free Cash Flow

$ -41.8M

-63.72 %

2018 Free Cash Flow

$ -25.5M

-13.76 %

2017 Free Cash Flow

$ -22.4M

-27.43 %

2016 Free Cash Flow

$ -17.6M

Madrigal Pharmaceuticals, Inc.(MDGL)